人体乳腺癌细胞系Bcap－37和MCF－7的细胞遗传学研究

应用低温同步法与秋水酰胺处理,对人体乳腺癌细胞系Ｂｃａｐ－３７和ＭＣＦ－７的中期及早中期细胞进行Ｇ－显带分析。研究表明,Ｂｃａｐ－３７细胞染色体众数为６３,可识别其结构的标记染色体１７条;ＭＣＦ－７细胞染色体众数为５６,可识别其结构的标记染色体１３条。结合文献报道以及本研究结果显示,乳腺癌中最常涉及到第１、３、５、７、１１、１３和１７号染色体结构及数目的异常,染色体断裂点１ｐ１１（１ｑ１１）、１ｐ１３、３ｐ２１、３ｑ１１、５ｑ１１、６ｑ１３、６ｑ２３、７ｑ２２、１１ｐ１３和１１ｐ１５也经常涉及;它们可能与癌相关基因的激活和抗癌基因的丢失有关,从而在乳腺癌发生发展中起一定作用。     

乳腺癌干细胞和乳腺癌

肿瘤干细胞既包含干细胞的特性也包含肿瘤细胞的特性。乳腺癌起源于乳腺癌干细胞的说法能够合理地解释乳腺癌的不均一性及其治疗后的复发,这些变异的干细胞可能作为肿瘤预防策略的靶标。而且,由于乳腺癌干细胞能够抵抗辐射治疗和化学治疗,所以要想更好地治疗乳腺癌就需要寻找针对这些干细胞的靶标。我们综述了乳腺癌干细胞的发现、富集和分离、相关的信号途径,以及在乳腺癌治疗中的应用。     

三阴性乳腺癌中Ki-67 的表达及其临床病理意义

目的:探讨三阴性乳腺癌中Ki-67的表达及其临床病理意义。方法:回顾性分析2010年11月1日至2015年12月31日辽宁省肿瘤医院收治的110例行乳腺癌根治术的三阴性乳腺癌患者的临床病理资料,检测其乳腺癌组织中Ki-67的表达,并分析其与患者年龄、绝经情况、组织学分型、临床分期、淋巴结转移、肿瘤大小等临床病理资料的关系。进一步采用Kaplan-Meier生存分析法绘制生存曲线,比较高表达Ki-67和低表达Ki-67患者的3年、5年生存率。结果:Ki-67在三阴性乳腺癌患者50岁以下和50岁以上相比较,差异具有统计学意义(P0.05);Ki-67在三阴性乳腺癌患者绝经情况、组织学分型、临床分期、淋巴结转移、肿瘤大小的表达相比较,差异不具有统计学意义(P0.05);高表达Ki-67组3年生存率为79.49%,5年生存率为30.77%;低Ki-67组的3年生存率为85.92%,5年生存率为46.48%;两组3年生存率相比较差异不具有统计学意义(P0.05);两组5年生存率相比较差异具有统计学意义(P0.05);两组总生存时间相比较,差异具有统计学意义(P0.05)。结论:三阴性乳腺癌中Ki-67呈高表达,可作为乳腺癌预后不良的危险因素。     

三阴乳腺癌新辅助化疗的预后与Ki-67、TOPK的表达情况相关性研究

摘要 目的：研究三阴乳腺癌（TNBC）新辅助化疗（NACT）的预后与Ki-67、TOPK的表达情况的相关性。方法：回顾性收集2014年3月至2016年6月期间我院收治并行NACT的TNBC患者90例作为研究对象,免疫组化法检测肿瘤组织中Ki-67和TOPK的表达,分析两者的表达与患者临床资料的关系,应用COX回归模型进行生存分析,分析影响TNBC患者预后的独立危险因素。结果：在治疗情况方面,91.11 %（82/90）的患者接受了≥4个周期的NACT治疗,84.44 %（76/90）的患者接受了手术治疗,术后pCR为22.22 %（20/90）,ORR为75.56 %（68/90）。为期5年的随访中,90例患者中共死亡8例（死于TNBC者6例,其他原因2例）,失访2例;治疗后Ki-67和TOPK的阳性率均显著低于治疗前（P＜0.05）;Ki-67、TOPK阳性和阴性表达病例在不同TNM分期、淋巴结是否转移上具有显著性差异（P＜0.05）;Ki-67和TOPK阳性表达患者的无进展生存期（PFS）和总生存期（OS）显著短于阴性表达者（P＜0.05）;TNM分期、淋巴结转移、Ki-67和TOPK阳性表达均为影响TNBC患者预后的独立危险因素。结论：Ki-67和TOPK在TNBC组织中的表达与患者的病理学特征及预后密切相关,是影响预后的独立危险因素。     

Transgelin Silencing Induces Different Processes in Different Breast Cancer Cell Lines

Transgelin is a protein reported to be a marker of several cancers. However, previous studies have shown both up‐ and down‐regulation of transgelin in tumors when compared with non‐tumor tissues and the mechanisms whereby transgelin may affect the development of cancer remain largely unknown. Transgelin is especially abundant in smooth muscle cells and is associated with actin stress fibers. These contractile structures participate in cell motility, adhesion, and the maintenance of cell morphology. Here, the role of transgelin in breast cancer is focused on. Initially, the effects of transgelin on cell migration of the breast cancer cell lines, BT 549 and PMC 42, is studied. Interestingly, transgelin silencing increased the migration of PMC 42 cells, but decreased the migration of BT 549 cells. To clarify these contradictory results, the changes in protein abundances after transgelin silencing in these two cell lines are analyzed using quantitative proteomics. The results confirmed the role of transgelin in the migration of BT 549 cells and suggest the involvement of transgelin in apoptosis and small molecule biochemistry in PMC 42 cells. The context‐dependent function of transgelin reflects the different molecular backgrounds of these cell lines, which differ in karyotypes, mutation statuses, and proteome profiles.     

HMGB1在胃癌组织及细胞系中表达的研究

目的:近年来的研究表明,高迁移率族蛋白(1HMGB1)在肿瘤的发生及恶性演变过程中发挥重要作用,本研究旨在探讨HMGB1在胃癌组织、正常组织、胃癌细胞系SGC-7901、BGC-823、HGC-27、AGS及正常胃黏膜细胞系GES中表达情况。方法:免疫组织化学法检测HMGB1在32例可手术切除的胃癌患者组织标本(包括癌组织和正常组织)的表达情况;RT-PCR及Westren Blot检测HMGB1在胃癌细胞系SGC-7901、BGC-823、HGC-27、AGS及正常胃粘膜细胞系GES的m RNA及蛋白质表达。结果:胃癌组织HMGB1免疫组织化学染色评分高于正常组织(P0.05);RT-PCR结果显示SGC-7901、BGC-823、HGC-27、AGS、GES细胞系HMGB1 m RNA表达丰度均较高;Westren Blot检测发现胃癌细胞系SGC-7901、BGC-823、HGC-27中HMGB1蛋白水平显著高于胃癌细胞系AGS及正常胃粘膜细胞系GES。结论:HMGB1在胃癌组织及正常组织中的表达具有显著性差异。胃癌细胞系SGC-7901、BGC-823、HGC-27相对于其它胃细胞系存在HMGB1高表达,适合后续基因敲除分析工作。     

Biological Screening of Polyphenol Derivatives for Anti-Proliferative,Anti-Apoptotic and Anti-Migrative Activities in Human Breast Cancer Cell Lines MCF-7

Breast cancer is known as the most common type of invasive cancer in women. It is well-known that phenolic compounds play an important role in the treatment of this disease. This study hypothesized that isoeugenol based two polyphenolic compounds 1 and 2 exerts its anti-proliferative effects through the induction of apoptosis and cell migration arrest on human breast cancer cell. Based on this hypothesis, the study aimed to investigate the anti-proliferative, anti-migrative effects of these compounds and their possible basic molecular mechanisms of action in MCF-7 cell lines. As a result, isoeugenol-based compounds 1 and 2 showed anti-proliferative, anti-apoptotic and anti-migrative effects in MCF-7 breast cancer cells. This result was supported by molecular analyzes and it was determined that there were changes in the expression of some gene regions involved in apoptosis and migration. Additionally, it was a remarkable result that cell viability inhibition did not occur in healthy breast tissue cells and no cytotoxic effect was observed. The existence of such a differentiation between cancer cells and healthy cells significantly increases the potential of these compounds to be used as chemotherapeutic drug active ingredients without side effects.     

筛选MDA-MB-231乳腺癌耐药细胞株两种方法的比较

目的 比较间歇刺激法和浓度梯度递增法对雌激素受体（estrogen receptor,ER）阴性的乳腺癌耐药细胞株的建立,为进一步探讨ER阴性乳腺癌可能的耐药机制.方法 采用间歇刺激法和浓度梯度递增法,用紫杉醇诱导6个月,分别建立了耐药细胞系231 TIM10和231 TAX8,并用倒置相差显微镜、MTT法、Western印迹、流式细胞术比较了两株耐药细胞的形态学变化、耐药表型、ER-α蛋白表达及紫杉醇诱导细胞G2/M期阻滞效应的改变等生物学特性.结果 间歇刺激法比浓度梯度递增法更容易诱导ER阴性的乳腺癌细胞获得耐药表型,231 TIM10耐药指数为11.9,231 TAX8耐药指数为2.3.用紫杉醇处理后,231 TIM10细胞能够抵抗100 nmol/L紫杉醇引起的G2/M期阻滞效应,231 TAX8细胞仅能够抵抗10 nmol/L紫杉醇引起的G2/M期阻滞效应.231 TIM10细胞在诱导过程中形成了两个细胞亚群,体积增大明显,细胞之间黏连更加明显.MDA-MB-231敏感细胞和两株耐药细胞均无ER-α蛋白的表达.结论 间歇刺激法更合理地模拟了临床上ER阴性乳腺癌的耐药过程,建立了可靠的细胞耐药模型,为耐药机制研究建立了基础.     

Decreased Expression of Cilia Genes in Pancreatic Islets as a Risk Factor for Type 2 Diabetes in Mice and Humans

1. Download high-res image (153KB)
2. Download full-size image

     

Fine Needle Aspiration Cytodiagnosis As A Pre-Requisite For Primary Medical Treatment of Breast Cancer

The accurate non-surgical diagnosis of breast lumps allows assessment of breast cancer patients for conservation or neoadjuvant primary treatment before surgical intervention. We have analysed the accuracy of clinical assessment, fine needle aspiration cytology (FNAC), and mammography in over 868 women seen in a symptomatic breast clinic. Clinical examination by an experienced breast physician, together with FNAC, detected over 99% of the cancers with a 12% false positive rate. A cytological diagnosis of definite carcinoma was obtained in 69% of women with breast cancer with no false positive result from the women with benign conditions producing a 100% positive predictive value. These results indicate that it would be acceptable to give pre-surgical systemic endocrine or chemotherapy to women with positive cytology which is therefore a prerequisite for a neoadjuvant therapy programme.     

鼠源性人乳腺癌单链抗体库的构建与乳腺癌相关抗体的筛选

目的:获得乳腺癌的噬菌体呈现型单链抗体(scFv)库,筛选与乳腺癌细胞特异结合的抗体,为乳腺癌的诊断和治疗奠定基础。方法:用乳腺癌细胞系MCF-7、T47D、MDA-MB-435免疫BALB/c小鼠,取脾脏提取总RNA,用RT-PCR分别扩增抗体重、轻链可变区(VH和VL)基因,经Linker连接形成scFv基因片段。将scFv基因片段与噬菌粒载体pCANTAB5E的连接产物转化大肠杆菌TG1。用辅助噬菌体M13KO7进行超感染,获得重组噬菌体抗体。选用乳腺癌细胞系MCF-7和人正常肝细胞系HL02做正负差异的筛选细胞,通过5轮筛选,随机挑取克隆,经phage-ELISA筛选特异性结合MCF-7细胞的scFv。结果:构建了1个库容为1.3×106的单链抗体库。筛选到2株与MCF-7细胞有较高结合活性的噬菌体-单链抗体scFv-873和scFv-874。数据库搜索表明这2株单链抗体基因是与以往抗体序列不同的新基因。用Westernblot检测了这2株单链抗体在琥珀密码子非抑制型菌株TOP10中的表达情况。结论:筛选到2个与乳腺癌细胞结合特异性较好的单链抗体,为乳腺癌的诊断和治疗研究奠定了基础。     

染色体着丝粒中结构蛋白CenpB的基因在乳腺癌组织中的活跃表达

利用Northern印迹技术对31例乳腺癌组织块及每一例病人的癌旁正常(非癌性)组织块进行分析,发现多数情况下(87．1％)癌组织中着丝粒蛋白CenpB mRNA过表达;组织原位杂交分析表明,在CenpB mRNA过表达的乳腺癌组织中,呈现出比癌旁正常组织更强的杂交信号;用免疫印迹法研究同样的标本,结果与RNA水平上的研究高度一致。结果显示,CenpB基因的过表达可能与乳腺细胞恶性增殖有关。     

两种人乳腺癌裸鼠移植模型的建立

目的建立简便的人乳腺癌裸鼠移植模型,并探讨其部分生物学特性。方法采用雌激素受体阴性的MDA-MB-231和SK-BR-3人乳腺癌细胞株,分别接种于10只裸鼠左侧腋窝皮下,移植细胞总数为1×107/只。观察肿块生长情况,第42天处死荷瘤鼠,切除肿块作病理切片。结果 MDA-MB-231接种后第5d在接种部位可见结节,成瘤率为90%（9/10）,接种42 d肿瘤体积426.6±333.8,瘤重0.417±0.276,病理学检查为浸润性导管癌;SK-BR-3接种后第11天在接种部位可见结节,成瘤率为80%（8/10）,接种42 d肿瘤体积357.5±246,瘤重0.325±0.167,病理学检查为浸润性导管癌。结论该方法建立的人乳腺癌裸鼠移植模型,皮下移植方法简单,易于操作,成功率较高,肿瘤可部分保持人乳腺癌生物学特性,为研究人乳腺癌提供了重要工具。     

KAI1基因转染人乳腺癌细胞系的建立及初步研究

目的:通过将外源性KAI1基因转染入高转移性人乳腺癌细胞株,为乳腺癌基因治疗的实验室研究提供靶细胞,并初步探讨该基因对乳腺癌细胞增殖能力及细胞周期的影响。方法:采用脂质体法将pCMV-KAI1质粒转染入低表达KAIl基因的人乳腺癌细胞株MDA-MB-231中,经G418筛选后获得抗性克隆,利用RT-PCR、Western blot分析目的基因及其蛋白的表达情况,并利用MTT法和平板克隆形成实验初步探讨该基因对乳腺癌细胞体外增殖能力的影响,流式细胞术检测细胞生长周期的变化。结果:稳定转染KAI1基因的细胞株中有外源性目的基因和相应蛋白的高表达;MTT法示细胞增殖力下降,转染KAI1基因的集落形成率(25.33 2.36)％较转染前(43．17 2．75)％明显降低(P<0．05),流式细胞术显示转染KAI1基因后G1／G0期细胞数量由未转染前的(36．78 0．61)％升高至(64 7．56)％,M／G2期细胞数量则由(17．88 0．76)％降至(7．63 0．60)％,差异有显著性。结论:通过脂质体转染法获得了高表达KAI1基因及其蛋白的人乳腺癌细胞株,并发现该细胞株的体外增殖能力明显下降,这可能是KAI1基因通过调节细胞周期来实现的。     

格列卫与多西紫杉醇联合对人乳腺癌细胞株MCF-7及其裸鼠移植瘤的作用

目的：探讨分子靶向药物格列卫与多西紫杉醇联合对人乳腺癌细胞株MCF-7的凋亡及其裸鼠皮下移植瘤生长的影响。方法：采用流式细胞检测仪检测MCF-7细胞在格列卫与多西紫杉醇单独处理及共同处理条件下的凋亡率;建立人乳腺癌细胞株MCF-7裸鼠皮下移植瘤模型,观察格列卫与多西紫杉醇单独治疗组及联合治疗组移植瘤的生长,计算抑瘤率。结果：MCF-7细胞在格列卫与多西紫杉醇共同处理条件下的凋亡率（50.86%）远高于多西紫杉醇单独处理（22.06%）及同剂量格列卫组单独处理（8.13%）条件下的凋亡率;高剂量多西紫杉醇与格列卫联合组肿瘤质量与单独多西紫杉醇组比较,差异虽然没有显著性,但联合组抑瘤率高达99.55%,高于多西紫杉醇组（97.43%）,q值为1.014;中剂量多西紫杉醇与格列卫联合组肿瘤质量与单独多西紫杉醇组比较,差异有高度显著性,联合组抑瘤率达96.53%,高于多西紫杉醇组（92.01%）,q值为1.02;低剂量多西紫杉醇与格列卫联合组肿瘤质量与单独多西紫杉醇组比较,差异有高度显著性,联合组抑瘤率达68.20%,高于多西紫杉醇组（58.40%）,q值为1.004。结论：格列卫与凋亡诱导剂多西紫杉醇共同处理MCF—7细胞能达到协同诱导凋亡的效果;高、中、低剂量的多西紫杉醇与格列卫联合对人乳腺癌细胞株MCF-7裸鼠移植瘤增殖的抑制具有相加作用。     

Tumor Cell Identification in Ki-67 Images on Deep Learning

The proportion of cells staining for the nuclear antigen Ki-67 is an important predictive indicator for assessment of tumor cell proliferation and growth in routine pathological investigation. Instead of traditional scoring methods based on the experience of a trained laboratory scientist, deep learning approach can be automatically used to analyze the expression of Ki-67 as well. Deep learning based on convolutional neural networks (CNN) for image classification and single shot multibox detector (SSD) for object detection are used to investigate the expression of Ki-67 for assessment of biopsies from patients with breast cancer in this study. The results focus on estimating the probability heatmap of tumor cells using CNN with accuracy of 98% and detecting the tumor cells using SSD with accuracy of 90%. This deep learning framework will provide an objective basis for the malignant degree of breast tumors and be beneficial to the pathologists for fast and efficiently Ki-67 scoring.     

Analysis of Gut Microbiota in Patients with Breast Cancer and Benign Breast Lesions

Breast cancer (BC) and benign breast lesions (BBLs) are common diseases in women worldwide. The gut microbiota plays a vital role in regulating breast diseases’ formation, progression, and therapy response. Hence, we explored the structure and function of gut microflora in patients with BC and BBLs. A cohort of 66 subjects was enrolled in the study. Twenty-six subjects had BC, 20 subjects had BBLs, and 20 matched healthy controls. High throughput 16S ribosomal RNA (16S rRNA) gene sequencing technology was used to determine the microbial community structure. Compared with healthy individuals, BC patients had significantly lower alpha diversity indices (Sobs index, p = 0.019; Chao1 index, p = 0.033). Sobs and Chao1 indices were also lower in patients with BBLs than healthy individuals, without statistical significance (p = 0.279, p = 0.314, respectively). Both unweighted and weighted UniFrac analysis showed that beta diversity differed significantly among the three groups (p = 3.376e–14, p < 0.001, respectively). Compared with healthy individuals, the levels of Porphyromonas and Peptoniphilus were higher in BC patients (p = 0.004, p = 0.007, respectively), whereas Escherichia and Lactobacillus were more enriched in the benign breast lesion group (p < 0.001, p = 0.011, respectively). Our study indicates that patients with BC and BBLs may undergo significant changes in intestinal microbiota. These findings can help elucidate the role of intestinal flora in BC and BBLs patients. Open in a separate window     

Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines

Lung cancer (LC) with its different subtypes is generally known as a therapy resistant cancer with the highest morbidity rate worldwide. Therapy resistance of a tumor is thought to be related to cancer stem cells (CSCs) within the tumors. There have been indications that the lung cancer is propagated and maintained by a small population of CSCs. To study this question we established a panel of 15 primary lung cancer cell lines (PLCCLs) from 20 fresh primary tumors using a robust serum-free culture system. We subsequently focused on identification of lung CSCs by studying these cell lines derived from 4 representative lung cancer subtypes such as small cell lung cancer (SCLC), large cell carcinoma (LCC), squamous cell carcinoma (SCC) and adenocarcinoma (AC). We identified a small population of cells strongly positive for CD44 (CD44^high) and a main population which was either weakly positive or negative for CD44 (CD44^low/−). Co-expression of CD90 further narrowed down the putative stem cell population in PLCCLs from SCLC and LCC as spheroid-forming cells were mainly found within the CD44^highCD90⁺ sub-population. Moreover, these CD44^highCD90⁺ cells revealed mesenchymal morphology, increased expression of mesenchymal markers N-Cadherin and Vimentin, increased mRNA levels of the embryonic stem cell related genes Nanog and Oct4 and increased resistance to irradiation compared to other sub-populations studied, suggesting the CD44^highCD90⁺ population a good candidate for the lung CSCs. Both CD44^highCD90⁺ and CD44^highCD90⁻ cells in the PLCCL derived from SCC formed spheroids, whereas the CD44^low/− cells were lacking this potential. These results indicate that CD44^highCD90⁺ sub-population may represent CSCs in SCLC and LCC, whereas in SCC lung cancer subtype, CSC potentials were found within the CD44^high sub-population.